Trial Profile
A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Confirmed by a Pathogenic Variant in the RPGR Gene
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Laruparetigene zovaparvovec (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- Acronyms HORIZON
- Sponsors Applied Genetic Technologies Corporation; Beacon Therapeutics
- 16 Feb 2024 The efficacy primary end point in the Phase 2 Dose Expansion part is removed, thus safety is the only trial focus.
- 16 Feb 2024 Planned End Date changed from 1 Aug 2026 to 1 Mar 2025.
- 16 Feb 2024 Status changed from recruiting to active, no longer recruiting.